Viridian Therapeutics Stock (NASDAQ: VRDN)

Viridian Therapeutics Stock (NASDAQ:VRDN), Trade Ideas

Viridian Therapeutics

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

covid-19-5169689

News

VRDN

Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten public offering.

Here&#39;s Why Viridian Therapeutics (VRDN) Stock Is Moving

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

CIFR

FANH

IGMS

JRVR

PGTI

PRTC

RILY

SMCI

ZIMV

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday.

ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday

BGNE

DAWN

DCPH

GTLS

IBRX

LITE

NRDS

SMMT

TGTX

VTRU

ZLAB

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics Inc

<a href="https://www.lvmh.com/news-documents/press-releases/lvmh-achieves-3-organic-revenue-growth-in-the-first-quarter/" title="https://www.lvmh.com/news-documents/press-releases/lvmh-achieves-3-organic-revenue-growth-in-the-first-quarter/">https://www.lvmh.com/news-documents/press-releases/lvmh-achieves-3-organic-revenue-growth-in-the-first-quarter/</a>

Earnings

LVMHF

LVMH Q1 2024 Revenue €20.7B

On Tuesday, Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) delivered a rather mixed first quarter report.&nbsp;Adjusted earnings&nbsp;surpassed&nbsp;estimates&nbsp;as sales in its medical devices business surged, while revenue was almost in line with estimates. First quarter results came shortly after JNJ&rsquo;s&nbsp;expansion in the cardiovascular space with the&nbsp;$13.1 billion acquisition of heart device firm&nbsp;Shockwave Medical Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swav#NASDAQ">SWAV</a>).
<h3>First Quarter Highlights</h3>
For the period ended in March,&nbsp;the healthcare company&nbsp;posted a revenue of&nbsp;$21.38 billion, almost in line with LSEG&rsquo;s estimate of&nbsp;$21.4 billion. During the first three months of the year, revenue rose more than 2% YoY. JNJ reported a&nbsp;net income of $5.35 billion, or $2.20 per share, with adjusted income amounting to&nbsp;$2.71, surpassing LSEG&rsquo;s estimate of&nbsp;$2.64. It is quite a difference compared to last year&rsquo;s comparable quarter when JNJ posted a net loss due to costs related to its controversial&nbsp;talc baby powder liabilities&nbsp;that led to&nbsp;the spinoff of its consumer health unit. This quarter&rsquo;s success is owed to the thriving&nbsp;medical devices business&nbsp;that brought&nbsp;$7.82&nbsp;to the revenue table, rising more than&nbsp;4%&nbsp;on a YoY basis, with JNJ attributing the YoY rise to the acquisition of Abiomed.
On a less bright note, JNJ reported weak&nbsp;sales of vision care products and surgical devices.&nbsp;Vision products unit reported sales dropped&nbsp;3.3% to $1.26 billion, but JNJ is confident that there will be tremendous improvement going forward.
JNJ is also going strong against cancer.
Meanwhile, pharmaceutical sales brought in sales of&nbsp;$13.56 billion&nbsp;and grew about 1% YoY. However, the segment was brought down by its unpopular Covid vaccine as without it, pharmaceutical sales grew almost 7%. This growth is greatly owed to its cancer drugs, namely&nbsp;Darzalex,&nbsp;that treats&nbsp;multiple myeloma, and Erleada,&nbsp;a treatment forprostate cancer treatmet, along with other other oncology treatments such as&nbsp;Carvykti, a cell therapy&nbsp;that has been&nbsp;approved for a certain blood cancer. Analysts expect&nbsp;Dazalex&nbsp;to bring in sales of more than $11 billion&nbsp;this&nbsp;year, followed by Carvykti with&nbsp;$1.15 billion.
For two years now, JNJ has been making quite a few pushes into the cardiovascular space to strengthen the medical devices business upon the split from the consumer unit, as before Shockwave Medical, it already got&nbsp;Abiomed andLaminar.&nbsp;&nbsp;During the reported quarter,&nbsp;medical devices unit reported&nbsp;revenue of&nbsp;$7.82 billion&nbsp;boosted by strongdemand for Abiomed heart pumps, as well as&nbsp;devices used in wound closure surgeries, but analysts expected&nbsp;$7.88 billion.
But, the latest quarter shows it is also strengthening its position in the cancer battle,&nbsp;joining the efforts of Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) and Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) who are also turning to oncology to fight falling sales of Covid products. Both Pfizer and Moderna are betting big on cancer drugs to turn business around. Pfizer acquired the cancer drug maker specialist&nbsp;Seagen, thanks to which it expects&nbsp;to have&nbsp;at least eight blockbuster medicines by&nbsp;the end of the decade.&nbsp;Pfizer is going against&nbsp;four main types of cancer: breast cancer; genitourinary cancer,&nbsp;thoracic cancer,&nbsp;and&nbsp;hematology-oncology&nbsp;cancer. Meanwhile, Moderna developed&nbsp;an&nbsp;individualized cancer vaccine with Merck. Last year, Moderna reported mid-stage results of the combined treatment that were promising against melanoma.&nbsp;Last week, Moderna reported the treatment showed a&nbsp;positive response in an early-stage trial&nbsp;also in patients&nbsp;suffering from a type of&nbsp;head and neck cancer.&nbsp;Unsurprisingly, Moderna shares rose to a three month high upon the news last Tuesday.
<h3>A Narrowed Full Year Guidance</h3>
JNJ guided for full year sales between&nbsp;$88 billion to $88.4 billion, narrowing down its prior range from&nbsp;$87.8 billion to $88.6 billion.&nbsp;As for adjusted earnings, JNJ provided a range between&nbsp;$10.57&nbsp;and&nbsp;$10.72 per share, also narrowing down its prior forecast that was between&nbsp;$10.55&nbsp;and&nbsp;$10.75. However, considering that the acquisition of Shockwave Medical is&nbsp;expected to&nbsp;close in the middle of the year,&nbsp;it will undoubtedly alter JNJ&rsquo;s full year guidance.
JNJ is often viewed as a reflection of the healthcare industry trends. With its latest results,&nbsp;the pharmaceutical giantshowed the sector is determined in finally winning the battle against cancer.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

MRNA

SWAV

Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff

Jefferies analyst Andy Barish maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Hold and lowers the price target from $100 to $94.

Price Target

Analyst Ratings

SBUX

Jefferies Maintains Hold on Starbucks, Lowers Price Target to $94

Calidi Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NASDAQ">CLDI</a>) shares are trading lower by 59% to $0.25 during Tuesday&#8217;s session after the company announced the pricing of a <a href="https://www.benzinga.com/pressreleases/24/04/b38268667/calidi-biotherapeutics-inc-announces-pricing-of-6-1-million-public-offering">$6.1 million public offering</a>.
The offering includes various types of warrants with different exercise prices and expiration dates. The company plans to use the net proceeds for working capital, general corporate purposes, and pre-clinical and clinical trials. 
The offering is expected to close around April 18, pending customary closing conditions, with Ladenburg Thalmann &amp; Co. Inc. serving as the sole placement agent.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38265826/high-interest-rates-could-cause-more-things-to-break-in-us-economy-by-2025-warns-st">High-Interest Rates Could Cause &#8216;More Things To Break&#8217; In US Economy By 2025, Warns Strategist</a>
<h2 class="wp-block-heading">How To Buy CLDI Stock</h2>
By now you're likely curious about how to participate in the market for Calidi Biotherapeutics &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Calidi Biotherapeutics, which is trading at $0.28 as of publishing time, $100 would buy you 357.14 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CLDI has a 52-week high of $5.00 and a 52-week low of $0.25.

CLDI

Why Calidi Biotherapeutics (CLDI) Shares Are Down Over 50%

Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares are trading higher Tuesday after the company announced it has signed an exclusive 5-year in-license<a href="https://www.benzinga.com/pressreleases/24/04/ac38268700/jaguar-health-licenses-fda-approved-oral-mucositis-product-for-u-s-market-initiating-commercial-f"> agreement with Venture Life Group PLC.</a>
The Details:
The license agreement is for the U.S. market for Venture Life's FDA-approved prescription product, Gelclair. Gelclair is used for the treatment of oral mucositis, also called &#8220;chemo mouth.&#8221;&nbsp;
&#8220;We are very happy to have executed the in-license agreement for Gelclair &#8211; and thus to have initiated Jaguar&#8217;s commercial footprint in our core focus area of cancer supportive care,&#8221; said Lisa Conte, Jaguar&#8217;s president and CEO.
Jaguar Health shares are moving on heavy trading volume following the announcement with more than 240 million shares already traded in the session. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, the stock&#8217;s 100-day average volume is 46.306 million shares.
Related News: <a href="https://www.benzinga.com/news/24/04/38255034/whats-going-on-with-rivian-automotive-stock">What&#8217;s Going On With Rivian Automotive Stock?</a>
<h2 class="wp-block-heading">Should I Sell My JAGX Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Jaguar Health have decreased by 68.97% in the past year. An investor who bought shares of Jaguar Health at the beginning of the year would make a profit of $0.04 per share if they sold it today. The stock has risen 172.33% over the past month, meaning an investor who bought shares on Mar. 1 would see a capital gain of $0.05.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Jaguar Health stock currently has an RSI of 70.7, indicating overbought conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
JAGX Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Jaguar Health shares are up 49.5% at 18 cents at the time of publication Tuesday.
Image from Shutterstock

JAGX

Why Jaguar Health Stock Is Up Today

TD Cowen analyst Bill Kirk maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Buy and raises the price target from $87 to $92.

SCHW

TD Cowen Maintains Buy on Charles Schwab, Raises Price Target to $92

Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares are trading higher Tuesday after the company announced the completion of its analysis <a href="https://www.benzinga.com/pressreleases/24/04/g38268575/palisade-bio-successfully-demonstrates-bioactivation-of-pali-2108-in-ex-vivo-study-of-normal-healt">evaluating ex-vivo bioactivation of PALI-2108.</a>
The Details:
Palisade Bio said the findings demonstrated PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with ulcerative colitis (UC). The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time.
&#8220;The results from this study underscore our confidence in PALI-2108 as a targeted treatment for moderate-to-severe UC,&#8221; said Dr. Mitch Jones, CMO at Palisade Bio.&nbsp;
&#8220;The successful bioactivation of prodrug PALI-2108 into its active PDE4 inhibitor form at consistently high conversion rates over a 24-hour period in stool samples highlights its promise as an innovative therapeutic approach for managing UCl," Jones added.&nbsp;
Palisade Bio shares are trending on social media and moving on heavy trading volume Tuesday. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, more than 13.2 million shares have already been traded in the session, compared to the stock&#8217;s 100-day average of less than 192,000 shares.
Related News: <a href="https://www.benzinga.com/news/24/04/38255034/whats-going-on-with-rivian-automotive-stock">What&#8217;s Going On With Rivian Automotive Stock?</a>
<h2 class="wp-block-heading">How To Buy PALI Stock:</h2>
By now you're likely curious about how to participate in the market for Palisade Bio &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
PALI Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Palisade Bio shares are up 60.8% at $6.69 at the time of publication Tuesday.
Image: Myriams-Fotos from Pixabay

PALI

Why Palisade Bio Stock Is Soaring Today

Tuesday,&nbsp;IGC Pharma Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) released interim data from its Phase 2 clinical trial of IGC-AD1 for agitation in dementia&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38266079/igc-ad1s-interim-phase-2-data-show-a-reduction-in-alzheimers-agitation-at-week-two" rel="noreferrer noopener">associated with Alzheimer&#8217;s</a>.
The data demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer&#8217;s at week two&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37853677/alzheimers-focused-small-cap-firm-igc-pharma-releases-data-candidate-reduces-agitation-compared-t" rel="noreferrer noopener">compared to placebo</a>.
IGC-AD1 targets neuroinflammation and CB1 receptor dysfunction, and the investigational drug contains THC as one of two active pharmaceutical agents.&nbsp;
&#8220;We are excited to share that the interim results on the secondary outcome show that IGC-AD1 can provide fast relief with few side effects in reducing agitation in Alzheimer&#8217;s dementia compared to placebo,&#8221; said Ram Mukunda, CEO of IGC Pharma.
&#8220;Approximately 6.5 million individuals in the U.S. live with Alzheimer&#8217;s and a majority experience a medical syndrome called agitation in Alzheimer&#8217;s dementia&#8230;The interim data indicate early signs of potential clinical benefit with IGC-AD1 with infrequent treatment-limiting side effects,&#8221; added Mukunda.
The secondary outcome, as measured by the change in agitation versus placebo using a standard measurement scale, the Cohen Mansfield Agitation Inventory (CMAI) at baseline and week 2, exhibited an Effect Size (ES) of 0.79 (p=0.071), indicating a large magnitude of difference between the active and placebo groups.&nbsp;
For context, a study published in 2003 concluded that an effect size over 0.5 corresponds to a noticeable change to a careful observer, highlighting the notable impact of IGC-AD1.&nbsp;
In May 2023, the FDA approved&nbsp;Otsuka Holding Co Ltd&#8217;s&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/OTSKY#OTC">OTSKY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OTSKF#OTC">OTSKF</a>) Rexulti (brexpiprazole), an atypical antipsychotic, with a boxed warning. This approval followed a significantly larger 12-week Phase 3 trial, which showed a Cohen&#8217;s d effect size of 0.35, whereas IGC-AD1 showed an effect size of 0.79 in two weeks.
The ongoing 146-patient clinical trial is a multicenter, double-blind, randomized, placebo-controlled study designed to assess the safety and efficacy of IGC-AD1 in treating agitation in dementia due to Alzheimer&#8217;s.&nbsp;
Over 1,000 oral doses have been administered to date, with no dose-limiting adverse events observed.
Price Action: IGC shares are up 19.50% at $0.52 on the last check Tuesday.
Image: Wally Crawfish from Pixabay

Biotech

Cannabis

Health Care

OTSKF

OTSKY

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation

Jefferies analyst Andy Barish maintains Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) with a Hold and raises the price target from $455 to $480.

Jefferies Maintains Hold on Domino's Pizza, Raises Price Target to $480

High-rolling investors have positioned themselves bearish on Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SBUX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Starbucks. This is not a typical pattern.
The sentiment among these major traders is split, with 33% bullish and 66% bearish. Among all the options we identified, there was one put, amounting to $66,105, and 8 calls, totaling $342,645.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $75.0 and $95.0 for Starbucks, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Starbucks options trades today is 4536.25 with a total volume of 2,412.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Starbucks's big money trades within a strike price range of $75.0 to $95.0 over the last 30 days.
<h3>Starbucks Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713282387_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.6</td>
<td>$85.00</td>
<td>$72.0K</td>
<td>2.1K</td>
<td>189</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$5.65</td>
<td>$5.55</td>
<td>$5.65</td>
<td>$80.00</td>
<td>$66.1K</td>
<td>10</td>
<td>18</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$21.35</td>
<td>$18.95</td>
<td>$20.4</td>
<td>$75.00</td>
<td>$61.2K</td>
<td>6</td>
<td>30</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/21/24</td>
<td>$1.99</td>
<td>$1.95</td>
<td>$1.97</td>
<td>$90.00</td>
<td>$59.1K</td>
<td>17.5K</td>
<td>503</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$2.15</td>
<td>$2.12</td>
<td>$2.12</td>
<td>$90.00</td>
<td>$42.4K</td>
<td>17.5K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 38,000 stores across more than 80 countries as of the end of fiscal 2023. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
In light of the recent options history for Starbucks, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Starbucks</h3>
<ul>
<li>With a volume of 2,260,705, the price of SBUX is down -0.02% at $85.16. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 14 days.</li>
</ul>
<h3>Professional Analyst Ratings for Starbucks</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $104.0.
<ul>
<li>An analyst from JP Morgan persists with their Overweight rating on Starbucks, maintaining a target price of $100. </li>
<li>In a cautious move, an analyst from TD Cowen downgraded its rating to Hold, setting a price target of $100. </li>
<li>An analyst from Morgan Stanley persists with their Overweight rating on Starbucks, maintaining a target price of $115. </li>
<li>Maintaining their stance, an analyst from TD Cowen continues to hold a Hold rating for Starbucks, targeting a price of $100. </li>
<li>An analyst from Wells Fargo persists with their Overweight rating on Starbucks, maintaining a target price of $105. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Starbucks options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Spotlight on Starbucks: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bullish stance on American Airlines Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with AAL, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for American Airlines Gr.
This isn't normal.
The overall sentiment of these big-money traders is split between 87% bullish and 12%, bearish.
Out of all of the options we uncovered, 7 are puts, for a total amount of $706,283, and there was 1 call, for a total amount of $27,500.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $25.0 for American Airlines Gr over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for American Airlines Gr's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of American Airlines Gr's whale activity within a strike price range from $10.0 to $25.0 in the last 30 days. 
<h3>American Airlines Gr Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713282382_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.0</td>
<td>$12.1</td>
<td>$12.1</td>
<td>$25.00</td>
<td>$363.0K</td>
<td>0</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.13</td>
<td>$0.1</td>
<td>$0.12</td>
<td>$10.00</td>
<td>$120.0K</td>
<td>137.2K</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.4</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$16.00</td>
<td>$55.2K</td>
<td>9</td>
<td style="text-align: right;">135</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$0.53</td>
<td>$0.52</td>
<td>$0.52</td>
<td>$11.00</td>
<td>$45.6K</td>
<td>12.4K</td>
<td style="text-align: right;">184</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.4</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$16.00</td>
<td>$45.2K</td>
<td>9</td>
<td style="text-align: right;">135</td>
</tr>
</tbody>
</table>

<h3>About American Airlines Gr</h3>
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major U.S. hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of U.S. airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
After a thorough review of the options trading surrounding American Airlines Gr, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is American Airlines Gr Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 9,772,929, the AAL's price is up by 0.5%, now at $13.01. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 13 days.</li>
</ul>
<h3>Professional Analyst Ratings for American Airlines Gr</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $19.0.
<ul>
<li>An analyst from UBS has revised its rating downward to Buy, adjusting the price target to $19. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for American Airlines Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

American Airlines Gr's Options Frenzy: What You Need to Know

ADDYY

Adidas Q1 2024 Revenue EUR$5.46B, Gross Margin 51.2%

Whales with a lot of money to spend have taken a noticeably bearish stance on Celsius Holdings.
Looking at options history for Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 63% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $349,014 and 5, calls, for a total amount of $350,191.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $100.0 for Celsius Holdings over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Celsius Holdings's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Celsius Holdings's whale activity within a strike price range from $60.0 to $100.0 in the last 30 days. 
<h3>Celsius Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713282377_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$6.5</td>
<td>$5.7</td>
<td>$6.5</td>
<td>$80.00</td>
<td>$130.0K</td>
<td>3.9K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$1.69</td>
<td>$1.5</td>
<td>$1.52</td>
<td>$77.00</td>
<td>$127.1K</td>
<td>45</td>
<td style="text-align: right;">836</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$2.33</td>
<td>$2.25</td>
<td>$2.33</td>
<td>$100.00</td>
<td>$116.5K</td>
<td>1.8K</td>
<td style="text-align: right;">24</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$7.35</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$80.00</td>
<td>$65.0K</td>
<td>3.9K</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$80.00</td>
<td>$58.9K</td>
<td>3.9K</td>
<td style="text-align: right;">923</td>
</tr>
</tbody>
</table>

<h3>About Celsius Holdings</h3>
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages (including those that are naturally caffeinated with stevia), Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius focuses its time on branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
Following our analysis of the options activities associated with Celsius Holdings, we pivot to a closer look at the company's own performance.
<h3>Where Is Celsius Holdings Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,572,954, the price of CELH is down by -0.64%, reaching $73.02.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 21 days from now.</li>
</ul>
<h3>Expert Opinions on Celsius Holdings</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $75.0.
<ul>
<li>Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Celsius Holdings with a target price of $75. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Celsius Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

CELH

This Is What Whales Are Betting On Celsius Holdings

WIIM

Shares of homebuilder stocks are trading lower following a drop in US housing starts.

Jefferies analyst Alexander Slagle maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Hold and raises the price target from $47 to $48.

Jefferies Maintains Hold on Brinker International, Raises Price Target to $48

Nike Shares Move Higher; Adidas Reports Quarterly Results

Buy and hold and investors&nbsp;hold through the ups and downs of the market, but shorter-term traders, such as swing traders, can&#39;t afford to waste time or capital holding through significant drawdowns.&nbsp;
The percentage of stocks above their 50-day <a href="https://www.benzinga.com/money/simple-moving-average">simple moving average (SMA)</a> is a tool swing traders can use to assess market conditions. When more than 50% of stocks are above their respective SMAs, it will generally be easier to make money on the long side because more than half of stocks are in uptrends.&nbsp;
The 50-day SMA is not a perfect measure of a trend, but it does provide a crude measure of whether a stock is moving up or down.
When less than 50% of stocks are above their 50-day SMA, more stocks are declining or choppy, generally making&nbsp;it harder to make money on the long side. This is the state of stock market currently, as it fell below the 50% indicator threshold in mid-April.
There are multiple versions of the indicator tracking different baskets of stocks. Two to consider using are:
<ul>
<li>% of S&amp;P 500 stocks above their 50-day SMA</li>
<li>% of all US stocks above their 50-day SMA</li>
</ul>
While they often move similarly, sometimes they may each tell a different story which can help traders assess underlying strengths or weaknesses.
<a href="/files/u55920/spx_with_market_health_indicators.png" target="_blank"><img alt="" src="https://www.benzinga.com/files/u55920/sp_500_with_breadth_indicators.png" style="height:294px; width:624px" /></a>
On November 14, 2023, both indicators moved above the 50% line signaling more than 50% of stocks were trading above their 50-day moving averages or trending higher.
The S&amp;P 500 breadth indicator stayed above 50 until April 12, 2024. When the indicator drops below 50% it indicates tougher conditions are underway for long traders, so avoid taking long trades until the indicator moves back above 50.
The &quot;all US stocks&quot; version of the indicator stayed above the 50 line from November until Feb. 5, 2024. It then whipsawed the 50 line until falling significantly below in early to mid-April.
That the &quot;all US stocks&quot; indicator was near 50 the last couple of months shows that many stocks were not participating in the rally underway in the S&amp;P 500 (NSYEARCA: SPY). While the index did move up from February to the end of March, the price action was rather choppy, compared to the stronger rally that occurred in late 2023 and early 2024.&nbsp;
<h3>How To Use The &quot;% Of Stocks Above 50-Day&quot; Indicator</h3>
The indicator isn&#39;t a red light/green light indicator. Rather it can be used to increase or decrease capital allocation.&nbsp; When the indicator(s) moves above 50 begin allocating some capital to individual stocks (swing trades). As conditions improve and current trades are working, allocate more capital.&nbsp;
As the indicator falls back to 50, avoid taking new long trades and consider moving stop loss orders near the current price on existing trades (trailing stop loss) to lock in profits as conditions deteriorate.
No indicator is perfect. This one doesn&#39;t pinpoint exact highs or lows in price, but it does highlight when conditions tend to be favorable for taking long trades and when conditions aren&#39;t.
If you like the idea of this&nbsp;indicator, study how it moves and decide how you will personally use it. Write it down in your <a href="https://tradethatswing.com/a-complete-trading-plan-for-becoming-a-better-trader/">Trading Plan</a> - a written/typed document outlining how you will trade.
<h3>Where To Find These Breadth Indicators</h3>
The indicators can be found on various charting platforms. On Tradingview the symbols are S5FI (S&amp;P 500 version) and MMFI (all US stocks version).&nbsp;
On StockCharts the symbol is $SPXA50R (S&amp;P 500) and $NYA50R (NYSE...they don&#39;t have an &quot;all&quot; stocks version).
On other chart platforms, use the search box to find an index called &quot;percent of stocks above 50&quot; or some variation of that.
This is just one of multiple indicators that can be used to <a href="https://tradethatswing.com/when-to-buy-stocks-after-a-stock-market-correction">assess when a market bottom is like in</a> and it is time to start buying again, or when a rallying is fading it is time to get conservative.
Disclaimer: The author owns S&amp;P 500-related ETFs in a long-term buy-and-hold portfolio and is limiting short-term trade exposure on the long side until market conditions improve.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

ETFs

Breadth Indicator Turns Negative As S&P 500 Declines, Avoid Buying Till It Turns Positive

Guidance

LEGN

Legend Biotech Earlier Announced CARVYKTI Generated Approximately $157M In Net Trade Sales During The Quarter Ended Mar. 31.

<h4>Key Takeaways:</h4>
<ul>
<li>A unit of China Construction Bank has asked a court to liquidate Shimao Group, which had a net debt ratio of 473.2% at the end of last year</li>
<li>CCB Asia has taken legal action against three Hong Kong-listed Chinese real estate developers so far this year</li>
</ul>
By Li Shih Ta
A new phase of all-out war has begun in China&rsquo;s sagging real estate industry, pitting struggling developers against their increasingly militant creditors seeking to recoup billions of dollars they&rsquo;re owed.
Ever since a Hong Kong court ordered the liquidation of&nbsp;China Evergrande Group&nbsp;(3333.HK) in January, those creditors have been turning up their efforts to seek redress in court by filing liquidation requests, formally known as winding-up petitions. In a significant step, big state-owned banks, which typically don&rsquo;t act without approval from Beijing, are joining the campaign.&nbsp;
Shimao Group Holdings Ltd.&nbsp;(0813.HK), one of China&rsquo;s top real estate enterprises, became the latest to fall victim to such a court-based assault with its&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0408/2024040800016.pdf">announcement</a>&nbsp;last week that it was the subject of a liquidation petition filed by&nbsp;China Construction Bank (Asia) Corp. Ltd.&nbsp;(CCB Asia). The unit of China Construction Bank (CCB), one of China&rsquo;s &ldquo;Big Four&rdquo; state-owned banks, is owed HK$1.58 billion ($202 million) from the developer, whose embattled stock plunged 18.7% to a fresh record low on the day of the announcement.&nbsp;
Shimao said it would &ldquo;oppose the petition vigorously and continue to work towards an offshore restructuring that maximizes value for its stakeholders.&rdquo; The liquidation petition &ldquo;does not represent collective interests of the company&rsquo;s offshore creditors and other stakeholders,&rdquo; it added.
Shimao, which owns offices, residential buildings, hotels and shopping malls in Beijing, Shanghai, Hong Kong and other cities, is one of the many companies that have defaulted on their offshore debt since China tightened supervision of property developers in 2021. The company failed to make interest and principal payments on $1 billion of its offshore bonds in July 2022, and has so far defaulted on up to $11.7 billion in cumulative debt.
<h4>CCB gets aggressive</h4>
After 18 months of negotiations, Shimao first submitted terms for an offshore debt restructuring to its creditors last December. The company offered them a variety of options in March this year, including converting their debt into six- or nine-year notes or loans, or zero-coupon mandatory convertible bonds.
Among those choices, the convertible bond option allows creditors to convert their bonds into company shares at a conversion price of HK$8.50 per share after one year. However, creditors are less than enthusiastic about that option since the conversion price is more than 20 times the current stock price. A major creditor group holding more than 25% of the outstanding overseas bonds called the terms &ldquo;detrimental&rdquo; to creditors&rsquo; interests.
The long negotiation process and lack of results are severely testing creditors&rsquo; patience. One creditor, Deutsche Bank, had said the proposal was unacceptable and that it would prepare for legal action in Hong Kong. But now it seems that CCB Asia beat it to the punch.
This isn&rsquo;t CCB Asia&rsquo;s first legal action against a Chinese developer. In late February, the bank filed another winding-up petition against&nbsp;DaFa Properties&nbsp;(6111.HK), which owes it $360 million. It then filed a similar petition against&nbsp;Dexin&nbsp;(2019.HK), which owes it $350 million for 9.95% senior notes that came due in December 2022 as well as accrued interest.
<h4>Whitelisted projects</h4>
China launched a &ldquo;whitelist&rdquo; program for properties under development in January this year, with projects on the list given priority for financing from CCB and China&rsquo;s other top four lenders, including ICBC, Agricultural Bank of China, Bank of China and Bank of Communications. The program is expected to provide as much as 3.2 trillion yuan in loans for more than 8,200 residential projects, many of whose construction has slowed or stopped due to lack of funds.
It&rsquo;s worth noting that the whitelist program aims to guarantee delivery of projects under construction and isn&rsquo;t designed to rescue real estate companies. That means that even if a state-owned bank grants a loan to help a developer finish a project, the bank doesn&rsquo;t forfeit its right to take legal action involving other debts that developer might owe it.&nbsp;
The serious real estate downturn of the last two years has produced a bumper crop of related non-performing loans (NPLs) for the banking sector. After reviewing financial results of 27 large and medium-sized banks listed in Hong Kong, Japan&rsquo;s Nikkei found that total NPLs related to China&rsquo;s real estate sector rose by 27% year-on-year last year. CCB, which traditionally focused on the construction industry, saw the biggest increase in real estate NPLs among the four major state-owned banks.
CCB&rsquo;s latest&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0328/2024032802486.pdf">annual results</a>&nbsp;released at the end of last month show it had 48.2 billion yuan worth of real estate-related NPLs in 2023, up 43% from 33.6 billion yuan in 2022, the highest increase among the four major state-owned banks. That increase lifted its real estate NPL ratio to 5.6% from 4.4%.
<h4>No auditor opinion</h4>
The saying goes that &ldquo;God helps those who help themselves,&rdquo; and such self-help may be the only way out for China&rsquo;s big field of heavily indebted developers. In addition to debt restructuring, Shimao is also selling off quality assets and pushing for more sales in order to secure the funds it desperately needs to work out its crippled finances as quickly as possible. But that hasn&rsquo;t gone so well.
According to the company&rsquo;s latest financial report for last year, it brought in revenue of 59.5 billion yuan in 2023, down 5.7% year-on-year, and lost about 21 billion yuan, similar to its year-ago loss. As of the end of last year, Shimao had total assets of 543.3 billion yuan and total liabilities of 492 billion yuan, giving it a liabilities-to-asset ratio of 88.7%. Its net debt ratio swelled to 473.2% from 302.2% in 2022.
We should note that in Shimao&rsquo;s latest annual results, its auditor said it was &ldquo;unable to express an opinion&rdquo; on the report because the company &ldquo;may not be able to realize its assets and repay its debts in the normal course of business.&rdquo;
The fate of China&rsquo;s property developers has been much like a low-speed train wreck, with each new phase only starting after much wrangling in the previous period. The newest phase now appears underway as banks and other creditors start to take legal action to defend their rights and interests, meaning more real estate enterprises may soon follow in Shimao&rsquo;s footsteps.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Deadbeat Developer Debt Collection Enters New Phase With Shimao Liquidation

Boeing Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) has decided to buy 9.4 million gallons (35.6 million liters) of blended sustainable aviation fuel (SAF)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38272028/boeing-makes-its-largest-purchase-of-blended-sustainable-aviation-fuel" rel="noreferrer noopener">to support its 2024 U.S. commercial operations</a>.
This is the company&#8217;s largest annual SAF purchase, more than 60% higher than its buy in 2023.
SAF is made of 30% waste by-products such as fats, oils, and greases and 70% conventional jet fuel.
The decision is expected to support the Boeing ecoDemonstrator program and Boeing U.S. commercial operational flights.
Unblended, or neat SAF, can reduce carbon emissions up to 85% over the fuel&#8217;s life cycle.
Boeing will also purchase the CO2 emissions reduction associated with 5.4 million gallons of blended SAF through an accounting process called book-and-claim.
Boeing will receive 4 million gallons of the blended SAF into its fuel farms in the Pacific Northwest.
EPIC Fuels will provide 2.5 million gallons from Neste, and Avfuel will provide 1.5 million gallons of blended SAF from Neste.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38268829/boeing-severes-ties-with-lobbying-firm-involved-in-737-max-crisis-management-report" rel="noreferrer noopener">Boeing Severs Ties With Lobbying Firm Involved In 737 Max Crisis Management: Report</a>
Price Action: BA shares are trading higher by 0.55% at $168.75 on the last check Tuesday.
Photo Courtesy: Tada Images On Shutterstock.com

Equities

General

Boeing Ups Its Sustainability Game: Reveals Largest Ever Purchase Of Blended SAF

Analyst Thomas Smith of Leerink Partners reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report), with a price target of $45.00. ...

Buy Rating Affirmed for Viridian Therapeutics Amid Strong Clinical Progress and Market Potential

The market has been down on Viridian Therapeutics Inc (VRDN)  stock recently. VRDN gets a Bearish score from InvestorsObserver Stock Sentiment Indicator. Viridian Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on VRDN!See Full VRDN ReportWhat is Stock Sen

Is Viridian Therapeutics Inc (VRDN) a Stock to Watch After Gaining 2.34% This Week?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Inflation has been the scourge of American households since the Covid-19 disruption. But investors can attempt to beat rising prices with stocks under $20. While these enterprises may be cheap, they potentially offer plenty of pop.



Of course, one of the primary catalysts for low-priced securities is the accessibility factor. After all, not every brokerage offers fractional share ownership. Also, from a psychological standpoint, investors generally prefer owning whole-unit equities. If anything, the math is easier.



Second, stocks under $20 sit in a sweet spot where they&rsquo;re viable enterprises but they could potentially rise higher. They&rsquo;re still relatively unknown so the spotlight could help dramatically invigorate sentiment.



You should realize that this is a higher-risk, higher-reward category. If you can handle this reality, these cheap stocks under $20 might be what you&rsquo;re looking for.



<h2>Genius Sports (GENI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/04/genius-sports-300x169.jpg" alt="Genius sports logo. Genius Sports is a sports data and technology company that provides data management and integrity services."><div>Source: Karolis Kavolelis / Shutterstock.com</div></div>With the rising popularity of sports betting and other forms of engagement, Genius Sports (NYSE:<a href="https://investorplace.com/stock-quotes/geni-stock-quote/">GENI</a>) should be on your radar for stocks under $20. Per its <a href="https://finance.yahoo.com/quote/GENI/profile">public profile</a>, Genius engages in the development and sale of technology-led products and services to the sports, sports betting and sports media industries. Further, it offers technology infrastructure for the collection, integration and distribution of live data of sports leagues, among other services.



To be fair, the business has a spotty record when it comes to the earnings print. Last year, the best performance related to the bottom line was in the second quarter. Back then, the company posted a loss of 5 cents per share, matching analysts&rsquo; consensus expectations. Otherwise, the company incurred some bad misses.



That said, experts see a turnaround in the current fiscal year, anticipating a per-share loss of 18 cents atop revenue of $480.59 million. These are significantly better figures than last year&rsquo;s print of a loss of 32 cents and sales of just under $413 million.



The best part? Analysts rate GENI a <a href="https://www.tipranks.com/stocks/geni/forecast">unanimous strong buy</a> with an $8.79 average price target. That&rsquo;s an implied 53% upside potential, making it one of the stocks under $20 to consider.



<h2>SkyWater Technology (SKYT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/semiconductor1600c-300x169.jpg" alt="AI. Circuit board. Technology background. Central Computer Processors CPU concept. Motherboard digital chip. Tech science background. Integrated communication processor. 3D illustration representing semiconductor stocks. Semiconductors Stocks to Sell"><div>Source: Shutterstock</div></div>With so much emphasis placed on computer chips these days, investors may want to focus on SkyWater Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/skyt-stock-quote/">SKYT</a>). Per its <a href="https://finance.yahoo.com/quote/skyt/profile">corporate profile</a>, Skywater along with its subsidiaries operates as a pure-play technology foundry that engages in the provision of semiconductor development, manufacturing and packaging services in the U.S. Since the start of the year, SKYT gained almost 15% of equity value.



Thanks to the underlying relevance, there could be more gains on tap. For full disclosure, SkyWater missed its bottom-line target in Q2 2023, producing a loss of 14 cents per share. Analysts were anticipating a loss of 11 cents. However, the company pared down expected losses in the other quarters of fiscal year 2023.



For 2024, experts believe that SkyWater can post earnings per share of 3 cents atop revenue of $322.33 million. Further, the high-side estimate calls for EPS of 13 cents and sales of $333.8 million. For context, SkyWater posted a loss of 17 cents per share and sales of $286.68 million in 2023.



In closing, analysts peg SKYT as a <a href="https://www.tipranks.com/stocks/skyt/forecast">unanimous strong buy</a> with a $15 price target. It&rsquo;s another intriguing idea for stocks under $20.



<h2>Viridian Therapeutics (VRDN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div>A biotechnology firm, Viridian Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrdn-stock-quote/">VRDN</a>) discovers and <a href="https://finance.yahoo.com/quote/vrdn/profile">develops treatments for serious and rare diseases</a>. The company&rsquo;s product pipeline features VRDN-001, a monoclonal antibody currently in Phase 3 trials that has been developed for the treatment of thyroid eye disease. Admittedly, VRDN is a volatile investment, losing more than 22% of its value since the start of January. Still, for speculators, there could be something here.



For one thing, the company has posted some decent earnings performances, relatively speaking. For example, in Q3 of last year, Viridian&rsquo;s loss per share landed at $1.09. This was better than the expected loss of $1.27. It also narrowly beat in Q2, posting a loss of $1.27 versus an expected loss of $1.29. That said, the average earnings surprise for Q1 and Q4 sat at 46.4% below parity.



This year, the narrative may be tricky, with the average consensus calling for sales of $270,000. That doesn&rsquo;t sound like a lot, considering that last year&rsquo;s revenue tally was $314,000. However, experts believe that by 2025, the top line could soar to $8.3 million.



Analysts are clearly intrigued, rating VRDN a <a href="https://www.tipranks.com/stocks/vrdn/forecast">unanimous strong buy</a> with a $38.64 price target. That implies almost 123% upside potential, making Viridian one of the top stocks under $20.



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/finding-the-next-big-winners-3-stocks-you-can-snag-for-under-20/">Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20

Viridian Therapeutics (VRDN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger...

Viridian Therapeutics Leads in Thyroid Eye Disease Treatments: Superior Efficacy and Promising Pipeline Justify Buy Rating

Wedbush analyst Laura Chico has maintained their bullish stance on VRDN stock, giving a Buy rating today. Laura Chico has given his Buy rating due ...

Buy Rating Affirmed for Viridian Therapeutics Amid Strong Competitive Position and Promising Drug Prospects

Viridian Therapeutics (VRDN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda ...

Buy Rating Endorsed for Viridian Therapeutics' VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED Market

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Taysha Gene Therapies (TSHA – Research Report) and V...

Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viridian Therapeutics (VRDN – Research Report), Omni...

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)

Analyst Laura Chico of Wedbush maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report), retaining the price target of $40.00. Lau...

Buy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market Potential

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Prime Medicine, Inc. (PRME – Research Report), Arvin...

-

-

-

-

-

-

-

25% Off Benzinga's Most Powerful Trading Tools

-

-

-

-

-

-

-

Viridian Therapeutics Stock (NASDAQ:VRDN), Trade Ideas